- About Us
- Advertise
- Contact Us
- CureToday.com
- CancerNetwork.com
- OncLive.com
- OncNursingNews.com
- Do Not Sell My Information
- Privacy
- Terms & Conditions
© 2023 MJH Life Sciences™ , Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
Tennessee Oncology | Association Partnerships
Latest from Tennessee Oncology
Lenvatinib/Everolimus Vs Tivozanib Evaluated for Later-Line RCC
January 25, 2023
Video
Benjamin Garmezy, MD, discusses the choice of third-line therapies in patients with advanced renal cell carcinoma.
Trial of DS-6000a Elicits Early Efficacy/Safety Data in RCC and Ovarian Cancer
January 18, 2023
Video
Erika P. Hamilton, MD, discusses the findings from a phase 1 trial of DS-6000a in patients with advanced renal cell carcinoma and ovarian cancer.
Expanded Roles for Trastuzumab Deruxtecan in HER2+ Breast Cancer
January 09, 2023
Video
Erika P. Hamilton, MD, discusses the wide-ranging impacts of the introduction of fam-trastuzumab deruxtecan-nxki for patients with HER2-positive breast cancer.
Follow-Up Analyzes Safety of DESTINY-Breast03 for HER2+ Breast Cancer
November 15, 2022
Video
Erika P. Hamilton, MD, discusses the purpose of a safety follow-up analysis for the DESTINY-Breast03 trial of fam-trastuzumab deruxtecan-nxki in patients with HER2-positive breast cancer.
Roundtable Discussion: Hamilton Compares Therapy Options and Sequencing for Recurrent TNBC
September 25, 2022
Article
During a Targeted Oncology case-based roundtable event, Erika P. Hamilton, MD, discussed the choice of first- and second-line therapy for a patient with triple-negative breast cancer following adjuvant chemotherapy.
Phase 1 Trial Evaluates DS-6000a in RCC and Ovarian Cancer
September 06, 2022
Video
Erika P. Hamilton, MD, discusses the background of a phase 1 trial of DS-6000a in patients with advanced renal cell carcinoma and ovarian cancer.